738 related articles for article (PubMed ID: 26444287)
21. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
Qiu YP; Zhao K; Li X; Shi LW; Guo WD; Qi XR; Sui BY; Zhou RM
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1074-1078. PubMed ID: 28057111
[No Abstract] [Full Text] [Related]
22. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
[TBL] [Abstract][Full Text] [Related]
23. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
Front Public Health; 2021; 9():647725. PubMed ID: 34109145
[No Abstract] [Full Text] [Related]
25. Surveillance of the impact of pneumococcal conjugate vaccines in developing countries.
Rodgers GL; Klugman KP
Hum Vaccin Immunother; 2016; 12(2):417-20. PubMed ID: 26309055
[TBL] [Abstract][Full Text] [Related]
26. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
28. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
29. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of pneumococcal vaccination for infants in China.
Maurer KA; Chen HF; Wagner AL; Hegde ST; Patel T; Boulton ML; Hutton DW
Vaccine; 2016 Dec; 34(50):6343-6349. PubMed ID: 27810315
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Gouveia M; Jesus G; Inês M; Costa J; Borges M
Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children.
Castañeda-Orjuela C; Alvis-Guzmán N; Velandia-González M; De la Hoz-Restrepo F
Vaccine; 2012 Mar; 30(11):1936-43. PubMed ID: 22266291
[TBL] [Abstract][Full Text] [Related]
36. Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions.
Usuf E; Mackenzie G; Lowe-Jallow Y; Boye B; Atherly D; Suraratdecha C; Griffiths UK
Vaccine; 2014 Apr; 32(17):1975-81. PubMed ID: 24503271
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
van Hoek AJ; Miller E
PLoS One; 2016; 11(2):e0149540. PubMed ID: 26914907
[TBL] [Abstract][Full Text] [Related]
38. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
39. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.
Che D; Zhou H; He J; Wu B
BMC Health Serv Res; 2014 Feb; 14():56. PubMed ID: 24507480
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
